Eris Lifesciences gets nod to raise up to Rs 1250 crore via NCDs

21 May 2024 Evaluate

Eris Lifesciences has received approval for the issuance of Non-convertible Debentures (NCDs) for an amount aggregating up to Rs 1250 crore in one or multiple series through Private Placement. The Board of Directors of the company, in their meeting held on May 21, 2024, duly approved the same.

Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.


Eris Lifesciences Share Price

1451.15 -20.85 (-1.42%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×